Bone Marrow Failure Syndrome 6

Mendelian MONDO:0030015 Pathograph 17 Show in embeddings browser Inherited bone marrow failure syndrome Bone marrow failure syndrome

Bone marrow failure syndrome 6 (BMFS6; OMIM 618849) is an inherited bone marrow failure syndrome caused by germline heterozygous loss-of-function variants in MDM4, a negative regulator of p53. It was defined in 2020 in a single family with features suggestive of dyskeratosis congenita - marrow hypocellularity, short telomeres, tongue squamous cell carcinoma and acute myeloid leukaemia - carrying the p.T454M allele. A 2026 cohort of six further unrelated individuals with variable bone marrow failure and hypocellular myelodysplastic syndrome, presenting at a median age of 10 years across a range from four weeks to 53 years, established the gene at cohort scale and supplied the functional dissection. The mechanism inverts the usual reading of the p53 pathway in haematology. MDM4 restrains p53; halving MDM4 therefore does not damage a repair pathway, it removes a brake. The consequence is p53 hyperactivity in haematopoietic stem and progenitor cells, with impaired colony formation, reduced engraftment and reduced erythroid and myeloid output. The authors name the category directly: MDM4 deficiency is a TP53-activating syndrome. Two orthogonal engineered systems support the chain - CRISPR deletion of MDM4 in healthy-donor HSPCs, and patient-specific variants knocked into iPSCs - and complementation shows that both the p53-binding domain and the RING-finger domain are required for MDM4's haematopoietic function. The disease sits, on current evidence, inside the telomere biology disorders rather than beside them. The founding family had short telomeres, and the p.T454M knock-in mouse reproduces increased p53 activity, decreased telomere length and bone marrow failure together. The 2026 cohort paper does not report telomere measurements, so how consistent the telomere phenotype is across genotypes remains open - but the direction of travel is that p53 hyperactivity is itself a cause of telomere dysfunction, not merely a correlate of it. The most striking single observation is evolutionary rather than developmental: one patient who progressed to MDS had acquired somatic loss-of-function TP53 mutations. Read against the germline lesion this is not a second hit in the ordinary tumour-suppressor sense but its opposite - a somatic event that relieves the very p53 hyperactivity the germline variant causes, buying clonal fitness at the cost of losing p53 tumour suppression. The source calls this maladaptive somatic rescue, and it is curated here as its own node.

Ask OpenScientist

Ask a research question about Bone Marrow Failure Syndrome 6. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
5
Phenotypes
1
Hypotheses
3
Gaps
17
Pathograph
2
Genes
1
Variants
3
Medical Actions
4
Models
5
References
1
Deep Research
🏷

Classifications

Harrison's Part
ONCOLOGY HEMATOLOGY GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
Autosomal dominant HP:0000006
All reported variants are germline and heterozygous, and the mechanism is haploinsufficiency, so a single altered allele is sufficient. Expressivity is markedly variable: presentation ranged from four weeks to 53 years of age within the same six-person cohort.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:41758987 SUPPORT Human Clinical
"Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF..."
Documents germline heterozygous variants, including four null alleles, which together with the haploinsufficiency mechanism supports dominant inheritance.
PMID:32300648 SUPPORT Model Organism
"Variations in p53 activity markedly altered the phenotype of Mdm4 mutant mice, suggesting an explanation for the variable expressivity of disease symptoms in the family."
Offers a mechanism for the variable expressivity: p53 activity is itself the modifier, so background variation in the pathway shifts the phenotype. Graded MODEL_ORGANISM because the demonstration is in mice; the human expressivity it explains is reported in the same family.
◈

Mechanistic Hypotheses

1
BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
p53_activating_bmf EMERGING
The proposal is that the primary lesion is dosage of a p53 brake, not damage to a maintenance pathway. It predicts that the marrow phenotype should be rescuable by lowering p53 activity, that severity should track MDM4 dosage rather than accumulated damage, and that clonal evolution should preferentially select p53-pathway escape events - the last of which is exactly what the single reported somatic TP53 event looks like.
Pathograph links
Germline Heterozygous MDM4 Loss-of-Function Variants -> Loss of MDM4-Mediated p53 Restraint Halved MDM4 dosage removes a negative regulator of p53.
Loss of MDM4-Mediated p53 Restraint -> p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells Releasing the brake raises p53 transcriptional output.
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells -> Impaired HSPC Self-Renewal and Multilineage Output p53 hyperactivity constrains progenitor proliferation and differentiation.
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells -> Telomere Shortening Germline p53-pathway activation is proposed to cause telomere dysfunction rather than result from it.
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells -> Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue Sustained p53 pressure selects for clones that escape it, at the cost of losing p53 tumour suppression.
Telomere Shortening -> Bone Marrow Failure with Hypocellular Marrow Telomere dysfunction limits the replicative capacity of haematopoietic progenitors, compounding the direct p53-driven proliferative block.
?

Discussions and Knowledge Gaps

3
Is telomere shortening a consistent feature of MDM4-related bone marrow failure, or specific to the p.T454M founding family?
KNOWLEDGE GAP OPEN bmfs6_telomere_penetrance
Attached to
pathophysiology#Telomere Shortening
Short telomeres are documented in humans, but in one family carrying one allele. The 2026 cohort of six further individuals reports no telomere measurements at all, so the six genotypes that most broadened the allelic spectrum - four of them truncating rather than missense - are silent on exactly the axis the founding family established. Whether telomere shortening tracks all loss-of-function MDM4 alleles or is p.T454M-specific is therefore untested, and it matters clinically: telomere length is a front-line diagnostic in the telomere biology disorders, and a negative result would not currently exclude BMFS6.
Proposed experiments
Telomere length measurement across the reported MDM4 allelic spectrum
bmfs6_telomere_length_across_alleles
Measure leukocyte telomere length in carriers of the truncating MDM4 alleles from the 2026 cohort and compare against the p.T454M family and age-matched controls.
Would support
pathophysiology#Telomere Shortening
Supporting outcome
  • Telomere length below the first centile for age in truncating-allele carriers, comparable to the p.T454M family, would establish telomere shortening as a feature of MDM4 haploinsufficiency generally rather than of one missense allele.
Refuting outcome
  • Age-normal telomere length in truncating-allele carriers would confine the telomere phenotype to p.T454M and argue that this entry should not conform to telomere_attrition at the disease level.
Show evidence (1 reference)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
The single family in which the human telomere phenotype is documented.
Does the downregulation of telomere-maintenance genes seen when p53 is hyperactivated in mice occur in human MDM4-haploinsufficient cells?
HUMAN MODEL MISMATCH OPEN bmfs6_mouse_telomere_gene_program
Attached to
pathophysiology#Telomere Shortening
This is the narrower question that survives now that the human telomere phenotype is established. The p53-hyperactive mouse shows a specific molecular program - downregulation of Dkc1, Rtel1, Tinf2 and Terf1, all genes mutated in dyskeratosis congenita or implicated in aplastic anaemia - and that program is the mouse's proposed explanation for its short telomeres. No human MDM4 carrier has had telomere-maintenance gene expression measured, so the shortening is documented in humans while the mechanism producing it is not. The distinction matters because a different route to the same shortening would change what the telomere arm predicts about which tissues are affected.
Show evidence (2 references)
PMID:23770245 SUPPORT Model Organism
"Importantly, several genes involved in telomere metabolism were downregulated in p53Δ31/Δ31 cells, including Dyskerin, Rtel1, and Tinf2, which are mutated in dyskeratosis congenita, and Terf1, which is implicated in aplastic anemia."
The specific molecular program that would need to be looked for in human MDM4-haploinsufficient cells to close this gap.
PMID:23770245 SUPPORT Model Organism
"Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms."
Establishes that Mdm4 dosage is the variable driving the mouse phenotype, which is what makes this model informative for BMFS6 specifically.
How often do MDM4-haploinsufficient patients acquire somatic TP53 loss-of-function clones, and should they be screened for them?
KNOWLEDGE GAP OPEN bmfs6_p53_escape_surveillance
Attached to
pathophysiology#Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue
The observation is n=1 within a six-person cohort, and the source frames it as suggestive rather than established. It matters clinically out of proportion to its frequency: if p53-pathway escape is the routine evolutionary path in this disease, then serial somatic TP53 screening would be surveillance for the specific mechanism of leukaemic progression rather than a generic MDS work-up. Nothing yet supports a recommendation either way, and this entry makes none.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
The single observation the gap is about, including the source's own hedged framing.
⚙

Pathophysiology

8
Germline Heterozygous MDM4 Loss-of-Function Variants
Four null alleles (frameshift, nonsense and splice-site variants producing premature truncation, confirmed at transcript level by RNA sequencing) and two missense alleles across six unrelated individuals. The direction of effect is loss of function, which for a p53 antagonist means the pathway consequence is activation rather than loss.
BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
MDM4 hgnc:6974 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased MDM4 (hgnc:6974). hgnc:6974 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Genetic context variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Germline heterozygous loss-of-function MDM4 alleles acting by haploinsufficiency.
Downstream
Loss of MDM4-Mediated p53 Restraint Halved MDM4 dosage removes a negative regulator of p53. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Show evidence (2 references)
PMID:41758987 SUPPORT Human Clinical
"Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF..."
Establishes the causal gene and the allelic spectrum, with RNA-level confirmation that the null alleles truncate the transcript.
PMID:41758987 SUPPORT Human Clinical
"Mechanistically, MDM4 mutations are loss-of-function mutations leading to enhanced p53 activation."
States the direction of effect explicitly, which is what makes this a p53-activating rather than a p53-losing syndrome.
Loss of MDM4-Mediated p53 Restraint
MDM4's normal job is to hold p53 down. Complementation studies establish that this function needs two distinct parts of the protein - the p53-binding domain and the RING-finger domain - so a variant disabling either one is sufficient, which is consistent with the mixed null and missense allelic spectrum.
BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
negative regulation of signal transduction by p53 class mediator GO:1901797 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased negative regulation of signal transduction by p53 class mediator (GO:1901797). GO:1901797 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells Releasing the brake raises p53 transcriptional output. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"Complementation studies revealed both p53-binding and RING-finger domains as necessary for MDM4-mediated hematopoietic regulation."
Identifies the two protein domains through which MDM4 exerts its haematopoietic function, both required.
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
The central node. MDM4-haploinsufficient HSPCs show increased p53 activity; MDM4-mutant iPSCs show the same, read out as elevated p21 expression; and transcriptome analysis of iPSC-derived haematopoietic cells shows upregulation of the p53 pathway. The authors' summary conclusion is that MDM4 deficiency is a TP53-activating syndrome.
BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
hematopoietic stem cell CL:0000037 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hematopoietic stem cell (CL:0000037). CL:0000037 is a cell type from the Cell Ontology.
signal transduction by p53 class mediator GO:0072331 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased signal transduction by p53 class mediator (GO:0072331). GO:0072331 is a biological process from the Gene Ontology. ↑ INCREASED
Experimental models
CRISPR/Cas9 MDM4-deleted healthy-donor HSPCs PRIMARY CELL CULTURE Human primary HSPCs with engineered MDM4 haploinsufficiency reproduce the p53 hyperactivity and the functional haematopoietic deficit.
Animal models
Mdm4 p.T454M knock-in mouse Mouse recapitulates The patient allele raises p53 activity in vivo, confirming in a whole organism what the human cell systems show.
p53 C-terminal truncation (p53 delta-31) mouse, Mdm4-dosage sensitized Mouse partially recapitulates Reproduces the causal direction - increased p53 activity produces aplastic anaemia, and reducing Mdm4 makes it dramatically worse - but arrives there by truncating p53 rather than by an MDM4 variant.
Downstream
Impaired HSPC Self-Renewal and Multilineage Output p53 hyperactivity constrains progenitor proliferation and differentiation. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Telomere Shortening Germline p53-pathway activation is proposed to cause telomere dysfunction rather than result from it. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue Sustained p53 pressure selects for clones that escape it, at the cost of losing p53 tumour suppression. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Show evidence (3 references)
PMID:41758987 SUPPORT In Vitro
"The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
Direct demonstration in CRISPR-edited healthy-donor HSPCs that halving MDM4 raises p53 activity and costs haematopoietic function.
PMID:41758987 SUPPORT In Vitro
"Transcriptome analysis of iPSC-derived hematopoietic cells revealed upregulation of the p53 pathway."
Independent transcriptome-level confirmation of p53 pathway upregulation in a second engineered system.
PMID:41758987 SUPPORT Human Clinical
"Our findings establish MDM4 deficiency as a TP53-activating syndrome, with features of BMF and variable hematopoietic manifestations."
The authors' own classification of the disease category, which is the organising claim of this entry.
Impaired HSPC Self-Renewal and Multilineage Output
The functional cost of p53 hyperactivity, measured three ways: impaired colony-forming capacity, reduced engraftment potential in immunodeficient mice, and significantly reduced erythroid and myeloid cell yield from MDM4-mutant iPSCs. The lesion is on proliferation and differentiation capacity rather than on a single lineage, which is what makes the clinical picture a trilineage marrow failure rather than a single cytopenia.
hematopoietic stem cell CL:0000037 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hematopoietic stem cell (CL:0000037). CL:0000037 is a cell type from the Cell Ontology.
erythrocyte differentiation GO:0030218 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased erythrocyte differentiation (GO:0030218). GO:0030218 is a biological process from the Gene Ontology. ↓ DECREASED myeloid cell differentiation GO:0030099 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased myeloid cell differentiation (GO:0030099). GO:0030099 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
Patient-variant knock-in iPSC-derived hematopoiesis IPSC DERIVED MODEL Reduced erythroid and myeloid output with elevated p21, reproducing the multilineage deficit attributable to p53 hyperactivity.
Downstream
Bone Marrow Failure with Hypocellular Marrow Reduced progenitor output manifests as marrow hypocellularity and cytopenias.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
Demonstrates reduced output across two lineages in a confounder-free genetic background, with p21 as the p53-activity readout.
Bone Marrow Failure with Hypocellular Marrow
The clinical endpoint of the developmental arm: variable bone marrow failure phenotypes with hypocellular myelodysplastic syndrome, presenting across a very wide age range.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
Reports the clinical phenotype and its striking range of onset in the defining cohort.
Telomere Shortening
Germline activation of the p53 pathway shortens telomeres. This is a human finding before it is a mouse one: the founding family had short telomeres alongside marrow hypocellularity, and the p.T454M knock-in mouse then reproduced increased p53 activity and decreased telomere length together with bone marrow failure. The direction of causation matters - the authors' conclusion is that germline p53-pathway activation may *cause* telomere dysfunction, which inverts the usual reading in which short telomeres are the primary lesion and p53 the downstream sensor. Conformance is declared against the attrition node of `telomere_attrition` rather than against its DNA-damage/senescence node, because what is documented in BMFS6 is the shortening itself; the senescence step is inferred from the module, not measured in these patients.
BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
telomere maintenance GO:0000723 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased telomere maintenance (GO:0000723). GO:0000723 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Mdm4 p.T454M knock-in mouse Mouse recapitulates Reproduces increased p53 activity, decreased telomere length and bone marrow failure in one animal carrying the human allele.
Downstream
Bone Marrow Failure with Hypocellular Marrow Telomere dysfunction limits the replicative capacity of haematopoietic progenitors, compounding the direct p53-driven proliferative block. BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
Show evidence (3 references)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Short telomeres in human MDM4-mutation carriers, reported in the family that defined the disease. This is the human evidence for the telomere arm.
PMID:32300648 SUPPORT Model Organism
"Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
A knock-in of the patient allele reproduces p53 activation, telomere shortening and marrow failure together, which is what links the three in one causal chain rather than leaving them as co-occurring features.
PMID:32300648 SUPPORT Human Clinical
"Our data indicate that a germline activation of the p53 pathway may cause telomere dysfunction and point to polymorphisms affecting this pathway as potential genetic modifiers of telomere biology and bone marrow function."
States the causal direction - p53 activation upstream of telomere dysfunction - which is why this node sits downstream of p53 hyperactivation rather than upstream of it.
Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue
One patient who progressed to MDS acquired somatic loss-of-function TP53 mutations. The natural reading, and the one the source gives, is rescue: a clone that inactivates p53 escapes the growth disadvantage the germline MDM4 lesion imposes, and outcompetes its neighbours. It is maladaptive because the escape route runs through the loss of p53 tumour suppression, which is the classic substrate for progression to MDS and leukaemia. This is the inverse of the usual two-hit picture - the somatic event relieves the germline mechanism rather than compounding it.
TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Genetic context variant_origin: SOMATIC functional_impact_category: LOSS_OF_FUNCTION
Somatically acquired loss-of-function TP53 mutations in a patient who progressed to MDS, arising on the germline MDM4-haploinsufficient background.
Downstream
Progression to Myelodysplastic Syndrome and Leukemia Escaping p53 restraint also removes p53 tumour suppression from the escaping clone.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
Reports the somatic TP53 event and the authors' interpretation of it as maladaptive rescue of the germline p53-hyperactivity lesion.
Progression to Myelodysplastic Syndrome and Leukemia
Bone marrow failure syndromes in general carry a risk of evolution to myelodysplastic syndrome and leukaemia, and hypocellular MDS was part of the presenting phenotype in this cohort. Recorded as the shared endpoint of the two upstream arms.
Show evidence (2 references)
PMID:41758987 SUPPORT Human Clinical
"Bone marrow failure (BMF) syndromes are heterogeneous diseases characterized by impaired hematopoiesis and a risk of evolution to myelodysplastic syndrome (MDS) and leukemia."
Establishes MDS/leukaemia evolution as the recognised risk for this disease class. This is a class-level statement about BMF syndromes; the disease-specific evidence is the item below.
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Acute myeloid leukaemia in the founding family is disease-specific human evidence for leukaemic progression in BMFS6, not an inference from the disease class. The risk still has no quantified estimate.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bone Marrow Failure Syndrome 6 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Blood 2
Hypocellular Myelodysplastic Syndrome Myelodysplasia HP:0002863 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myelodysplasia (HP:0002863). HP:0002863 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
Records hypocellular MDS as part of the presenting phenotype.
Acute Myeloid Leukemia HP:0004808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acute myeloid leukemia (HP:0004808). HP:0004808 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Reports AML in MDM4-mutation carriers.
Other 3
Bone Marrow Failure Bone marrow hypocellularity HP:0005528 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bone marrow hypocellularity (HP:0005528). HP:0005528 is a phenotype from the Human Phenotype Ontology.
Sequelae: Hypocellular Myelodysplastic Syndrome
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
Reports bone marrow failure with a hypocellular marrow in all six individuals of the defining cohort.
Short Telomeres Short telomere length HP:0031413 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short telomere length (HP:0031413). HP:0031413 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Reports short telomeres in the human carriers of the p.T454M allele.
Squamous Cell Carcinoma of the Tongue HP:0030413 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Squamous cell carcinoma of the tongue (HP:0030413). HP:0030413 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Reports tongue squamous cell carcinoma in MDM4-mutation carriers.
🧬

Genetic Associations

2
MDM4
Gene: MDM4 hgnc:6974 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MDM4 (hgnc:6974). hgnc:6974 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:41758987 SUPPORT Human Clinical
"Mechanistically, MDM4 mutations are loss-of-function mutations leading to enhanced p53 activation."
States both the gene and the direction of effect that defines the mechanism.
PMID:41758987 SUPPORT In Vitro
"Complementation studies revealed both p53-binding and RING-finger domains as necessary for MDM4-mediated hematopoietic regulation."
Domain-level functional dissection supporting a specific, testable molecular role rather than a statistical association.
TP53
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: COOPERATING variant_origin: SOMATIC
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
Documents the somatic TP53 event and its proposed interpretation.
🔬

Variants

1
MDM4 p.Thr454Met
Gene: MDM4 hgnc:6974 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in MDM4 (hgnc:6974). hgnc:6974 is a gene from the HUGO Gene Nomenclature Committee. SNV
The founding allele, carried by the family in which BMFS6 was defined, and one of the two missense variants in the 2026 cohort - the one the cohort paper notes "had previously been associated with a familial BMF syndrome". It is the only MDM4 allele modelled as a knock-in mouse.
Show evidence (1 reference)
PMID:32300648 SUPPORT Model Organism
"Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
Functional characterisation of this specific allele in vivo.
💊

Medical Actions

3
Hematopoietic Stem Cell Transplantation
Action: hematopoietic stem cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic stem cell transplantation, annotated with Hematopoietic Cell Transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
Recorded from telomere-biology-disorder management guidance, not from BMFS6 data - no transplant outcome has been reported in an MDM4 carrier. The basis for importing it is that the founding family presented with features suggestive of dyskeratosis congenita and short telomeres, placing BMFS6 inside the class the source reviews. A reader should treat this as the expected standard of care for the class rather than as evidence about this gene.
Show evidence (1 reference)
PMID:35929966 SUPPORT INDIRECT Other
"Although hematological defects can respond to danazol/oxymetholone, the only current curative treatment for these is hematopoietic stem cell transplantation (HSCT) using fludarabine-based conditioning protocols."
Expert-view management statement for the telomere biology disorders. INDIRECT because the claim is about the disease class, and BMFS6's membership of that class rests on one family's phenotype.
Androgen Therapy (Danazol or Oxymetholone)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: danazol CHEBI:4315 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses danazol (CHEBI:4315). CHEBI:4315 is a therapeutic agent from Chemical Entities of Biological Interest. oxymetholone CHEBI:7864 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses oxymetholone (CHEBI:7864). CHEBI:7864 is a therapeutic agent from Chemical Entities of Biological Interest.
Also class-level. Androgens are the non-transplant option for the haematological defect in telomere biology disorders. Untested in BMFS6, and mechanistically untested against a p53-driven proliferative block - the same caveat as above applies with less supporting analogy, since the androgen response in telomere disorders is generally attributed to telomerase upregulation rather than to relief of p53 pressure.
Show evidence (1 reference)
PMID:35929966 SUPPORT INDIRECT Other
"Although hematological defects can respond to danazol/oxymetholone, the only current curative treatment for these is hematopoietic stem cell transplantation (HSCT) using fludarabine-based conditioning protocols."
Records the androgen option and, in the same sentence, its subordinate status to transplantation. INDIRECT for the same class-level reason.
MDM2/MDMX inhibitors (nutlins and successors) - contraindicated on mechanistic grounds
Category: Therapeutic Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Recorded as a treatment to avoid, not one to give, and recorded because it is the direct clinical consequence of this entry's organising claim. MDM2/MDMX inhibitors are developed for cancer precisely to raise p53 activity - that is their intended pharmacology, not a side effect. BMFS6 is a disease of p53 hyperactivity caused by losing half the dose of MDMX (MDM4). Giving a drug whose mechanism is inhibition of that same axis would be expected to deepen the causal lesion rather than treat it, and the haematopoietic compartment is the one already demonstrably intolerant of the p53 pressure. The strength of this claim needs stating precisely. No publication makes this recommendation about BMFS6; no MDM2/MDMX inhibitor has been given to an MDM4-haploinsufficient patient, and no adverse outcome has been reported. The cited evidence establishes only the pharmacological premise - that these agents work by raising p53 activity. The contraindication follows from that premise plus this entry's own mechanism, in one inference step, which is why it is graded INDIRECT. It is nonetheless worth curating rather than leaving implicit. These agents are in clinical evaluation for haematological malignancy, BMFS6 patients present with hypocellular MDS and progress to leukaemia, and one reported patient acquired somatic TP53 loss - so an MDM4-haploinsufficient person reaching an oncology setting where an MDM2/MDMX inhibitor is on the menu is a foreseeable situation rather than a hypothetical one.
Show evidence (1 reference)
PMID:28673313 SUPPORT INDIRECT Other
"The pharmacological targeting of these two P53-regulators in order to restore or increase P53 expression and activity represents therefore a strategy for cancer therapy."
Establishes that MDM2/MDMX inhibition raises p53 activity by design. INDIRECT because the source is about cancer therapy and says nothing about BMFS6; the contraindication is an inference from this pharmacology plus this entry's mechanism, not a reported finding.
🔬

Diagnosis

3
Bone Marrow Examination
Establishes marrow hypocellularity and identifies dysplastic change, which together define the presenting phenotype in this cohort.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
The presenting phenotype is defined on marrow cellularity and dysplasia.
Telomere Length Measurement
Worth performing, and worth interpreting cautiously. Short telomeres in the founding family are what first suggested a telomere biology disorder, so a short result supports the diagnosis - but the 2026 cohort was not measured, so a normal result does not currently exclude BMFS6.
Show evidence (1 reference)
PMID:32300648 SUPPORT Human Clinical
"a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
Short telomeres were part of the presentation that defined the disease.
Germline Molecular Genetic Testing of MDM4
Confirmatory. Note that four of the six reported alleles are truncating and were confirmed at transcript level by RNA sequencing, so RNA-level confirmation is worth having for splice-region candidates rather than relying on DNA-level prediction alone.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF..."
Documents the diagnostic finding and the RNA-level confirmation step.
📊

Prevalence

1
Worldwide, published cases
Cases In Literature Ultra Rare
One family (Toufektchan et al. 2020) plus six unrelated individuals (Sharma et al. 2026). No incidence or prevalence estimate has been published, and the two cohorts differ in ascertainment, so no rate is computed here.
Show evidence (1 reference)
PMID:41758987 SUPPORT Human Clinical
"We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
The six-person cohort that is the larger of the two published case sets.
🧫

Experimental Models

2
CRISPR/Cas9 MDM4-deleted healthy-donor HSPCs PRIMARY_CELL_CULTURE
MDM4 deleted in hematopoietic stem and progenitor cells from healthy donors, producing MDM4-haploinsufficient cells on an otherwise normal genetic background. This is the cleanest available test of dosage, since it isolates MDM4 copy number from patient genetic background.
Publication
PMID:41758987
Pathograph links
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells recapitulates fidelity: high Human primary HSPCs with engineered MDM4 haploinsufficiency reproduce the p53 hyperactivity and the functional haematopoietic deficit.
Limitations: Engineered deletion is not the patient allelic spectrum: four of the six patient alleles are truncating, but two are missense, and a missense allele may retain partial function or act differently from a clean deletion. Engraftment is scored in immunodeficient mice, so the readout is a xenograft niche rather than a human marrow.
Readouts
p53 transcriptional activity
Direction: INCREASED
Interpretation: Direct readout of the released p53 brake.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
Reports increased p53 activity in the edited HSPCs.
Colony-forming capacity
Direction: DECREASED
Interpretation: Functional cost of p53 hyperactivity to progenitor proliferation.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
Reports impaired colony formation in the edited HSPCs.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"We used CRISPR/Cas9 to delete MDM4 in healthy donor hematopoietic stem and progenitor cells (HSPCs)."
Establishes the model system and that it is built on healthy-donor human primary cells.
Patient-variant knock-in iPSC-derived hematopoiesis IPSC_DERIVED_MODEL
Patient-specific MDM4 variants introduced into induced pluripotent stem cells, explicitly to test variant effects in a confounder-free genetic background. Complements the CRISPR HSPC model by testing the actual patient alleles rather than a deletion.
Publication
PMID:41758987
Pathograph links
Impaired HSPC Self-Renewal and Multilineage Output recapitulates fidelity: moderate Reduced erythroid and myeloid output with elevated p21, reproducing the multilineage deficit attributable to p53 hyperactivity.
Limitations: iPSC-derived haematopoiesis is developmentally distinct from adult bone-marrow haematopoiesis and is generally biased toward primitive or yolk-sac-like programmes, so a differentiation deficit measured here is not straightforwardly a statement about adult marrow. The system also cannot model the marrow niche or the decades-long clonal dynamics that the somatic TP53 arm of this disease turns on.
Readouts
Erythroid and myeloid cell output
Direction: DECREASED
Interpretation: Multilineage differentiation deficit in the patient genotypes.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
Reports the reduced two-lineage output.
p21 expression
Direction: INCREASED
Interpretation: p53 transcriptional-target readout confirming pathway activation.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
p21 elevation is the reported p53-activity readout.
Show evidence (1 reference)
PMID:41758987 SUPPORT In Vitro
"To study variant effects in a confounder-free genetic background, we introduced patient-specific MDM4 variants into induced pluripotent stem cells (iPSCs)."
States the model and, usefully, the authors' reason for building it - isolating variant effect from patient background.
🐁

Animal Models

2
Mdm4 p.T454M knock-in mouse
A knock-in of the actual patient allele, which is what makes it the best-matched model available for this disease. It resolves the limitation that caps the p53-delta-31 mouse below it: the lesion is in Mdm4, not in p53.
Species
Mouse
Genotype
Mdm4 p.T454M knock-in (the founding-family patient allele)
Publication
PMID:32300648
Pathograph links
Telomere Shortening recapitulates fidelity: high Reproduces increased p53 activity, decreased telomere length and bone marrow failure in one animal carrying the human allele.
Limitations: Mouse telomeres are far longer than human telomeres and mice express telomerase more widely in somatic tissue, so the absolute shortening is not comparable and a mouse can tolerate attrition that would be pathological in a person. The model also covers only the missense p.T454M allele; the four truncating alleles from the 2026 cohort are unmodelled.
Readouts
Telomere length
Direction: DECREASED
Interpretation: Direct measurement of the telomere phenotype in the patient genotype.
Show evidence (1 reference)
PMID:32300648 SUPPORT Model Organism
"Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
Reports decreased telomere length in the knock-in.
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells recapitulates fidelity: high The patient allele raises p53 activity in vivo, confirming in a whole organism what the human cell systems show.
Limitations: p53 target-gene programs and the tolerance of tissues to p53 activation differ between mouse and human, so the magnitude of activation does not transfer.
Readouts
p53 activity
Direction: INCREASED
Interpretation: In vivo confirmation of the central mechanism.
Show evidence (1 reference)
PMID:32300648 SUPPORT Model Organism
"Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
Reports increased p53 activity in the knock-in.
Show evidence (1 reference)
PMID:32300648 SUPPORT Model Organism
"Variations in p53 activity markedly altered the phenotype of Mdm4 mutant mice, suggesting an explanation for the variable expressivity of disease symptoms in the family."
The model's most useful contribution beyond recapitulation: it supplies a mechanism for the variable expressivity seen in human carriers, by making p53 activity itself the modifier.
p53 C-terminal truncation (p53 delta-31) mouse, Mdm4-dosage sensitized
Not an MDM4 model in the first instance - it is a p53-activation model that was independently sensitized by lowering Mdm4. That makes it evidence about the axis rather than about the gene, which is why its fidelity is recorded as moderate and why its telomere findings are held in a HUMAN_MODEL_MISMATCH discussion rather than curated as human edges.
Species
Mouse
Genotype
Trp53 delta-31 (C-terminal domain deletion), homozygous and heterozygous; Mdm4 dosage reduced
Publication
PMID:23770245
Pathograph links
p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells partially recapitulates fidelity: moderate Reproduces the causal direction - increased p53 activity produces aplastic anaemia, and reducing Mdm4 makes it dramatically worse - but arrives there by truncating p53 rather than by an MDM4 variant.
Limitations: The primary lesion is in p53 itself, not MDM4; Mdm4 dosage enters as a modifier. The mouse also develops pulmonary fibrosis and short telomeres, neither of which has been reported in human BMFS6, so the model's phenotype is broader than the human disease as currently described.
Readouts
Aplastic anemia
Direction: INCREASED
Interpretation: Marrow failure arising directly from increased p53 activity, the mouse counterpart of the human haematopoietic phenotype.
Show evidence (1 reference)
PMID:23770245 SUPPORT Model Organism
"homozygous mutant mice expressing p53Δ31, a p53 lacking the C-terminal domain, exhibit increased p53 activity and suffer from aplastic anemia and pulmonary fibrosis, hallmarks of syndromes caused by short telomeres"
Reports the marrow phenotype in the p53-hyperactive mouse.
Show evidence (1 reference)
PMID:23770245 SUPPORT Model Organism
"Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms."
This is what makes the model informative for BMFS6 specifically: Mdm4 dosage is the variable that converts a mild phenotype into a severe one.
{ }

Source YAML

click to show 
name: Bone Marrow Failure Syndrome 6
creation_date: "2026-08-30T19:10:00Z"
category: Mendelian
disease_term:
  preferred_term: bone marrow failure syndrome 6
  term:
    id: MONDO:0030015
    label: bone marrow failure syndrome 6
description: >
  Bone marrow failure syndrome 6 (BMFS6; OMIM 618849) is an inherited bone
  marrow failure syndrome caused by germline heterozygous loss-of-function
  variants in MDM4, a negative regulator of p53. It was defined in 2020 in a
  single family with features suggestive of dyskeratosis congenita - marrow
  hypocellularity, short telomeres, tongue squamous cell carcinoma and acute
  myeloid leukaemia - carrying the p.T454M allele. A 2026 cohort of six further
  unrelated individuals with variable bone marrow failure and hypocellular
  myelodysplastic syndrome, presenting at a median age of 10 years across a
  range from four weeks to 53 years, established the gene at cohort scale and
  supplied the functional dissection.

  The mechanism inverts the usual reading of the p53 pathway in haematology.
  MDM4 restrains p53; halving MDM4 therefore does not damage a repair pathway,
  it removes a brake. The consequence is p53 hyperactivity in haematopoietic
  stem and progenitor cells, with impaired colony formation, reduced
  engraftment and reduced erythroid and myeloid output. The authors name the
  category directly: MDM4 deficiency is a TP53-activating syndrome. Two
  orthogonal engineered systems support the chain - CRISPR deletion of MDM4 in
  healthy-donor HSPCs, and patient-specific variants knocked into iPSCs - and
  complementation shows that both the p53-binding domain and the RING-finger
  domain are required for MDM4's haematopoietic function.

  The disease sits, on current evidence, inside the telomere biology disorders
  rather than beside them. The founding family had short telomeres, and the
  p.T454M knock-in mouse reproduces increased p53 activity, decreased telomere
  length and bone marrow failure together. The 2026 cohort paper does not
  report telomere measurements, so how consistent the telomere phenotype is
  across genotypes remains open - but the direction of travel is that p53
  hyperactivity is itself a cause of telomere dysfunction, not merely a
  correlate of it.

  The most striking single observation is evolutionary rather than
  developmental: one patient who progressed to MDS had acquired somatic
  loss-of-function TP53 mutations. Read against the germline lesion this is
  not a second hit in the ordinary tumour-suppressor sense but its opposite -
  a somatic event that relieves the very p53 hyperactivity the germline
  variant causes, buying clonal fitness at the cost of losing p53 tumour
  suppression. The source calls this maladaptive somatic rescue, and it is
  curated here as its own node.

synonyms:
  - BMFS6
  - MDM4 haploinsufficiency
  - MDM4 deficiency

parents:
  - Inherited bone marrow failure syndrome
  - Bone marrow failure syndrome

classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:41758987
      reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
      explanation: >
        A bone marrow failure syndrome with progression to myelodysplastic
        syndrome, placing it in Harrison's haematology/oncology Part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:41758987
      reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4)"
      explanation: >
        A germline monogenic disorder, placing it in Harrison's genetics Part.

inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    All reported variants are germline and heterozygous, and the mechanism is
    haploinsufficiency, so a single altered allele is sufficient. Expressivity
    is markedly variable: presentation ranged from four weeks to 53 years of
    age within the same six-person cohort.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF syndrome."
    explanation: >
      Documents germline heterozygous variants, including four null alleles,
      which together with the haploinsufficiency mechanism supports dominant
      inheritance.
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Variations in p53 activity markedly altered the phenotype of Mdm4 mutant mice, suggesting an explanation for the variable expressivity of disease symptoms in the family."
    explanation: >
      Offers a mechanism for the variable expressivity: p53 activity is itself
      the modifier, so background variation in the pathway shifts the
      phenotype. Graded MODEL_ORGANISM because the demonstration is in mice;
      the human expressivity it explains is reported in the same family.

notes: >
  Two source cohorts, and they must not be pooled. The founding report is one
  family (Toufektchan et al., Sci Adv 2020, the p.T454M allele); the
  gene-establishing cohort is six further unrelated individuals (Sharma et al.,
  Blood 2026). Counts in this entry name their denominator, and no `frequency`
  values are set - a band computed across seven people from two papers with
  different ascertainment would be a scope error.

  The OMIM clinical-synopsis cytopenias (anaemia, neutropenia, lymphopenia)
  are deliberately not curated as phenotypes. Neither BMFS6 primary paper
  states them, and the OMIM synopsis is not a citable source in this
  repository's evidence model, so adding them would mean an evidence item with
  no quotable origin. They are almost certainly real; they are simply not
  citable here yet.

  Two care notes for future curators. First, MONDO records no causal gene
  (RO:0004003) for MONDO:0030015, so the `stubs/` entry for this disease
  carried no `genes:` block and the gene identity has to come from OMIM
  #618849 or the primary literature, not from the stub. Second, and relatedly,
  BMFS6 is easy to confuse with MECOM-associated radioulnar synostosis with
  amegakaryocytic thrombocytopenia, which is a different OMIM entity; the
  claim issue for this entry (#10170) was initially filed with that wrong gene
  and has been corrected.

  `treatments:` is curated from a telomere-biology-disorder management review
  rather than from BMFS6-specific data, because neither BMFS6 primary paper
  discusses treatment. The one exception is the MDM2/MDMX-inhibitor
  contraindication, which is not imported from any disease class: it is derived
  from this entry's own mechanism plus the published pharmacology of those
  agents, and is marked INDIRECT for exactly that reason. It is curated rather
  than omitted because these drugs are in clinical evaluation for
  haematological malignancy, which is where a BMFS6 patient with hypocellular
  MDS could plausibly encounter them. No publication makes this recommendation
  about BMFS6 and the entry does not imply otherwise. Each treatment records that explicitly and carries
  `directness: INDIRECT`. The justification for importing class-level
  management is that the founding family was described as having features
  suggestive of dyskeratosis congenita with short telomeres, which places
  BMFS6 inside the class the review covers; it is not a claim that HSCT
  outcomes have been reported in MDM4 carriers.

prevalence:
- population: Worldwide, published cases
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    One family (Toufektchan et al. 2020) plus six unrelated individuals
    (Sharma et al. 2026). No incidence or prevalence estimate has been
    published, and the two cohorts differ in ascertainment, so no rate is
    computed here.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
    explanation: >-
      The six-person cohort that is the larger of the two published case sets.

pathophysiology:
- name: Germline Heterozygous MDM4 Loss-of-Function Variants
  biological_scale: MOLECULAR
  description: >
    Four null alleles (frameshift, nonsense and splice-site variants producing
    premature truncation, confirmed at transcript level by RNA sequencing) and
    two missense alleles across six unrelated individuals. The direction of
    effect is loss of function, which for a p53 antagonist means the pathway
    consequence is activation rather than loss.
  genes:
  - preferred_term: MDM4
    term:
      id: hgnc:6974
      label: MDM4
    modifier: DECREASED
  genetic_context:
    description: >-
      Germline heterozygous loss-of-function MDM4 alleles acting by
      haploinsufficiency.
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF syndrome."
    explanation: >
      Establishes the causal gene and the allelic spectrum, with RNA-level
      confirmation that the null alleles truncate the transcript.
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mechanistically, MDM4 mutations are loss-of-function mutations leading to enhanced p53 activation."
    explanation: >
      States the direction of effect explicitly, which is what makes this a
      p53-activating rather than a p53-losing syndrome.
  downstream:
  - target: Loss of MDM4-Mediated p53 Restraint
    description: Halved MDM4 dosage removes a negative regulator of p53.
    hypothesis_groups:
    - p53_activating_bmf

- name: Loss of MDM4-Mediated p53 Restraint
  biological_scale: MOLECULAR
  description: >
    MDM4's normal job is to hold p53 down. Complementation studies establish
    that this function needs two distinct parts of the protein - the
    p53-binding domain and the RING-finger domain - so a variant disabling
    either one is sufficient, which is consistent with the mixed null and
    missense allelic spectrum.
  biological_processes:
  - preferred_term: negative regulation of signal transduction by p53 class mediator
    modifier: DECREASED
    term:
      id: GO:1901797
      label: negative regulation of signal transduction by p53 class mediator
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Complementation studies revealed both p53-binding and RING-finger domains as necessary for MDM4-mediated hematopoietic regulation."
    explanation: >
      Identifies the two protein domains through which MDM4 exerts its
      haematopoietic function, both required.
  downstream:
  - target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
    description: Releasing the brake raises p53 transcriptional output.
    hypothesis_groups:
    - p53_activating_bmf

- name: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
  biological_scale: CELLULAR
  description: >
    The central node. MDM4-haploinsufficient HSPCs show increased p53
    activity; MDM4-mutant iPSCs show the same, read out as elevated p21
    expression; and transcriptome analysis of iPSC-derived haematopoietic
    cells shows upregulation of the p53 pathway. The authors' summary
    conclusion is that MDM4 deficiency is a TP53-activating syndrome.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: INCREASED
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
    explanation: >
      Direct demonstration in CRISPR-edited healthy-donor HSPCs that halving
      MDM4 raises p53 activity and costs haematopoietic function.
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Transcriptome analysis of iPSC-derived hematopoietic cells revealed upregulation of the p53 pathway."
    explanation: >
      Independent transcriptome-level confirmation of p53 pathway
      upregulation in a second engineered system.
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings establish MDM4 deficiency as a TP53-activating syndrome, with features of BMF and variable hematopoietic manifestations."
    explanation: >
      The authors' own classification of the disease category, which is the
      organising claim of this entry.
  downstream:
  - target: Impaired HSPC Self-Renewal and Multilineage Output
    description: p53 hyperactivity constrains progenitor proliferation and differentiation.
    hypothesis_groups:
    - p53_activating_bmf
  - target: Telomere Shortening
    description: >
      Germline p53-pathway activation is proposed to cause telomere
      dysfunction rather than result from it.
    hypothesis_groups:
    - p53_activating_bmf
  - target: Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue
    description: >
      Sustained p53 pressure selects for clones that escape it, at the cost of
      losing p53 tumour suppression.
    hypothesis_groups:
    - p53_activating_bmf

- name: Impaired HSPC Self-Renewal and Multilineage Output
  biological_scale: CELLULAR
  description: >
    The functional cost of p53 hyperactivity, measured three ways: impaired
    colony-forming capacity, reduced engraftment potential in immunodeficient
    mice, and significantly reduced erythroid and myeloid cell yield from
    MDM4-mutant iPSCs. The lesion is on proliferation and differentiation
    capacity rather than on a single lineage, which is what makes the clinical
    picture a trilineage marrow failure rather than a single cytopenia.
  cell_types:
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: erythrocyte differentiation
    modifier: DECREASED
    term:
      id: GO:0030218
      label: erythrocyte differentiation
  - preferred_term: myeloid cell differentiation
    modifier: DECREASED
    term:
      id: GO:0030099
      label: myeloid cell differentiation
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
    explanation: >
      Demonstrates reduced output across two lineages in a
      confounder-free genetic background, with p21 as the p53-activity
      readout.
  downstream:
  - target: Bone Marrow Failure with Hypocellular Marrow
    description: Reduced progenitor output manifests as marrow hypocellularity and cytopenias.

- name: Bone Marrow Failure with Hypocellular Marrow
  biological_scale: TISSUE
  description: >
    The clinical endpoint of the developmental arm: variable bone marrow
    failure phenotypes with hypocellular myelodysplastic syndrome, presenting
    across a very wide age range.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
    explanation: >
      Reports the clinical phenotype and its striking range of onset in the
      defining cohort.

- name: Telomere Shortening
  biological_scale: MOLECULAR
  conforms_to: "telomere_attrition#Progressive Telomere Attrition"
  description: >
    Germline activation of the p53 pathway shortens telomeres. This is a human
    finding before it is a mouse one: the founding family had short telomeres
    alongside marrow hypocellularity, and the p.T454M knock-in mouse then
    reproduced increased p53 activity and decreased telomere length together
    with bone marrow failure. The direction of causation matters - the authors'
    conclusion is that germline p53-pathway activation may *cause* telomere
    dysfunction, which inverts the usual reading in which short telomeres are
    the primary lesion and p53 the downstream sensor.

    Conformance is declared against the attrition node of `telomere_attrition`
    rather than against its DNA-damage/senescence node, because what is
    documented in BMFS6 is the shortening itself; the senescence step is
    inferred from the module, not measured in these patients.
  biological_processes:
  - preferred_term: telomere maintenance
    modifier: DECREASED
    term:
      id: GO:0000723
      label: telomere maintenance
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Short telomeres in human MDM4-mutation carriers, reported in the family
      that defined the disease. This is the human evidence for the telomere
      arm.
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
    explanation: >
      A knock-in of the patient allele reproduces p53 activation, telomere
      shortening and marrow failure together, which is what links the three in
      one causal chain rather than leaving them as co-occurring features.
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data indicate that a germline activation of the p53 pathway may cause telomere dysfunction and point to polymorphisms affecting this pathway as potential genetic modifiers of telomere biology and bone marrow function."
    explanation: >
      States the causal direction - p53 activation upstream of telomere
      dysfunction - which is why this node sits downstream of p53
      hyperactivation rather than upstream of it.
  downstream:
  - target: Bone Marrow Failure with Hypocellular Marrow
    description: >
      Telomere dysfunction limits the replicative capacity of haematopoietic
      progenitors, compounding the direct p53-driven proliferative block.
    hypothesis_groups:
    - p53_activating_bmf

- name: Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue
  biological_scale: CELLULAR
  description: >
    One patient who progressed to MDS acquired somatic loss-of-function TP53
    mutations. The natural reading, and the one the source gives, is rescue: a
    clone that inactivates p53 escapes the growth disadvantage the germline
    MDM4 lesion imposes, and outcompetes its neighbours. It is maladaptive
    because the escape route runs through the loss of p53 tumour suppression,
    which is the classic substrate for progression to MDS and leukaemia. This
    is the inverse of the usual two-hit picture - the somatic event relieves
    the germline mechanism rather than compounding it.
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
    modifier: DECREASED
  genetic_context:
    description: >-
      Somatically acquired loss-of-function TP53 mutations in a patient who
      progressed to MDS, arising on the germline MDM4-haploinsufficient
      background.
    variant_origin: SOMATIC
    functional_impact_category: LOSS_OF_FUNCTION
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
    explanation: >
      Reports the somatic TP53 event and the authors' interpretation of it as
      maladaptive rescue of the germline p53-hyperactivity lesion.
  downstream:
  - target: Progression to Myelodysplastic Syndrome and Leukemia
    description: >
      Escaping p53 restraint also removes p53 tumour suppression from the
      escaping clone.

- name: Progression to Myelodysplastic Syndrome and Leukemia
  biological_scale: ORGANISM
  description: >
    Bone marrow failure syndromes in general carry a risk of evolution to
    myelodysplastic syndrome and leukaemia, and hypocellular MDS was part of
    the presenting phenotype in this cohort. Recorded as the shared endpoint
    of the two upstream arms.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone marrow failure (BMF) syndromes are heterogeneous diseases characterized by impaired hematopoiesis and a risk of evolution to myelodysplastic syndrome (MDS) and leukemia."
    explanation: >
      Establishes MDS/leukaemia evolution as the recognised risk for this
      disease class. This is a class-level statement about BMF syndromes; the
      disease-specific evidence is the item below.
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Acute myeloid leukaemia in the founding family is disease-specific human
      evidence for leukaemic progression in BMFS6, not an inference from the
      disease class. The risk still has no quantified estimate.

mechanistic_hypotheses:
- hypothesis_group_id: p53_activating_bmf
  hypothesis_label: BMFS6 is a p53-activating syndrome rather than a DNA-repair or telomere syndrome
  status: EMERGING
  description: >
    The proposal is that the primary lesion is dosage of a p53 brake, not
    damage to a maintenance pathway. It predicts that the marrow phenotype
    should be rescuable by lowering p53 activity, that severity should track
    MDM4 dosage rather than accumulated damage, and that clonal evolution
    should preferentially select p53-pathway escape events - the last of which
    is exactly what the single reported somatic TP53 event looks like.

discussions:
- discussion_id: bmfs6_telomere_penetrance
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Telomere Shortening
  prompt: >-
    Is telomere shortening a consistent feature of MDM4-related bone marrow
    failure, or specific to the p.T454M founding family?
  rationale: >-
    Short telomeres are documented in humans, but in one family carrying one
    allele. The 2026 cohort of six further individuals reports no telomere
    measurements at all, so the six genotypes that most broadened the allelic
    spectrum - four of them truncating rather than missense - are silent on
    exactly the axis the founding family established. Whether telomere
    shortening tracks all loss-of-function MDM4 alleles or is p.T454M-specific
    is therefore untested, and it matters clinically: telomere length is a
    front-line diagnostic in the telomere biology disorders, and a negative
    result would not currently exclude BMFS6.
  proposed_experiments:
  - experiment_id: bmfs6_telomere_length_across_alleles
    name: Telomere length measurement across the reported MDM4 allelic spectrum
    description: >-
      Measure leukocyte telomere length in carriers of the truncating MDM4
      alleles from the 2026 cohort and compare against the p.T454M family and
      age-matched controls.
    would_support:
    - pathophysiology#Telomere Shortening
    supporting_outcome:
    - >-
      Telomere length below the first centile for age in truncating-allele
      carriers, comparable to the p.T454M family, would establish telomere
      shortening as a feature of MDM4 haploinsufficiency generally rather than
      of one missense allele.
    refuting_outcome:
    - >-
      Age-normal telomere length in truncating-allele carriers would confine
      the telomere phenotype to p.T454M and argue that this entry should not
      conform to telomere_attrition at the disease level.
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >-
      The single family in which the human telomere phenotype is documented.

- discussion_id: bmfs6_mouse_telomere_gene_program
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Telomere Shortening
  prompt: >-
    Does the downregulation of telomere-maintenance genes seen when p53 is
    hyperactivated in mice occur in human MDM4-haploinsufficient cells?
  rationale: >-
    This is the narrower question that survives now that the human telomere
    phenotype is established. The p53-hyperactive mouse shows a specific
    molecular program - downregulation of Dkc1, Rtel1, Tinf2 and Terf1, all
    genes mutated in dyskeratosis congenita or implicated in aplastic anaemia -
    and that program is the mouse's proposed explanation for its short
    telomeres. No human MDM4 carrier has had telomere-maintenance gene
    expression measured, so the shortening is documented in humans while the
    mechanism producing it is not. The distinction matters because a different
    route to the same shortening would change what the telomere arm predicts
    about which tissues are affected.
  evidence:
  - reference: PMID:23770245
    reference_title: "Mutant mice lacking the p53 C-terminal domain model telomere syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Importantly, several genes involved in telomere metabolism were downregulated in p53Δ31/Δ31 cells, including Dyskerin, Rtel1, and Tinf2, which are mutated in dyskeratosis congenita, and Terf1, which is implicated in aplastic anemia."
    explanation: >-
      The specific molecular program that would need to be looked for in human
      MDM4-haploinsufficient cells to close this gap.
  - reference: PMID:23770245
    reference_title: "Mutant mice lacking the p53 C-terminal domain model telomere syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms."
    explanation: >-
      Establishes that Mdm4 dosage is the variable driving the mouse phenotype,
      which is what makes this model informative for BMFS6 specifically.

- discussion_id: bmfs6_p53_escape_surveillance
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic TP53 Loss-of-Function as Maladaptive Clonal Rescue
  prompt: >-
    How often do MDM4-haploinsufficient patients acquire somatic TP53
    loss-of-function clones, and should they be screened for them?
  rationale: >-
    The observation is n=1 within a six-person cohort, and the source frames it
    as suggestive rather than established. It matters clinically out of
    proportion to its frequency: if p53-pathway escape is the routine
    evolutionary path in this disease, then serial somatic TP53 screening
    would be surveillance for the specific mechanism of leukaemic progression
    rather than a generic MDS work-up. Nothing yet supports a recommendation
    either way, and this entry makes none.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
    explanation: >-
      The single observation the gap is about, including the source's own
      hedged framing.

phenotypes:
- category: Hematologic
  name: Bone Marrow Failure
  description: >
    Variable in severity across the cohort, and remarkably variable in timing -
    a median presentation age of 10 years across a range from four weeks to 53
    years, within six people carrying variants in one gene. An adult
    presentation therefore does not argue against the diagnosis.
  phenotype_term:
    preferred_term: Bone marrow hypocellularity
    term:
      id: HP:0005528
      label: Bone marrow hypocellularity
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
    explanation: >
      Reports bone marrow failure with a hypocellular marrow in all six
      individuals of the defining cohort.
  sequelae:
  - target: Hypocellular Myelodysplastic Syndrome
    description: >
      Marrow failure in this cohort presented together with, or progressed to,
      hypocellular MDS.

- category: Hematologic
  name: Hypocellular Myelodysplastic Syndrome
  description: >
    Present in the defining cohort alongside the marrow failure. One patient
    with MDS was the individual who had acquired somatic TP53 loss-of-function
    mutations.
  phenotype_term:
    preferred_term: Myelodysplasia
    term:
      id: HP:0002863
      label: Myelodysplasia
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
    explanation: >
      Records hypocellular MDS as part of the presenting phenotype.

- category: Hematologic
  name: Short Telomeres
  description: >
    Documented in the founding family alongside marrow hypocellularity, as one
    of the features that made the presentation resemble dyskeratosis congenita.
    Not measured in the 2026 cohort - see the penetrance gap above.
  phenotype_term:
    preferred_term: Short telomere length
    term:
      id: HP:0031413
      label: Short telomere length
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Reports short telomeres in the human carriers of the p.T454M allele.

- category: Neoplastic
  name: Acute Myeloid Leukemia
  description: >
    Reported in the founding family. This is disease-specific human evidence
    for leukaemic progression, as distinct from the class-level statement that
    bone marrow failure syndromes carry that risk.
  phenotype_term:
    preferred_term: Acute myeloid leukemia
    term:
      id: HP:0004808
      label: Acute myeloid leukemia
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Reports AML in MDM4-mutation carriers.

- category: Neoplastic
  name: Squamous Cell Carcinoma of the Tongue
  description: >
    A non-haematopoietic cancer, reported in the founding family. Worth
    recording separately from the marrow phenotype: it establishes that the
    cancer predisposition in this disease is not confined to the
    haematopoietic compartment, which is also the pattern in the telomere
    biology disorders this family was thought to resemble.
  phenotype_term:
    preferred_term: Squamous cell carcinoma of the tongue
    term:
      id: HP:0030413
      label: Squamous cell carcinoma of the tongue
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Reports tongue squamous cell carcinoma in MDM4-mutation carriers.

experimental_models:
- name: CRISPR/Cas9 MDM4-deleted healthy-donor HSPCs
  description: >
    MDM4 deleted in hematopoietic stem and progenitor cells from healthy
    donors, producing MDM4-haploinsufficient cells on an otherwise normal
    genetic background. This is the cleanest available test of dosage, since
    it isolates MDM4 copy number from patient genetic background.
  experimental_model_type: PRIMARY_CELL_CULTURE
  publication: PMID:41758987
  modeled_mechanisms:
  - target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >
      Human primary HSPCs with engineered MDM4 haploinsufficiency reproduce
      the p53 hyperactivity and the functional haematopoietic deficit.
    limitations: >-
      Engineered deletion is not the patient allelic spectrum: four of the six
      patient alleles are truncating, but two are missense, and a missense
      allele may retain partial function or act differently from a clean
      deletion. Engraftment is scored in immunodeficient mice, so the readout
      is a xenograft niche rather than a human marrow.
    readouts:
    - name: p53 transcriptional activity
      target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
      direction: INCREASED
      interpretation: Direct readout of the released p53 brake.
      evidence:
      - reference: PMID:41758987
        reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
        explanation: Reports increased p53 activity in the edited HSPCs.
    - name: Colony-forming capacity
      target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
      direction: DECREASED
      interpretation: Functional cost of p53 hyperactivity to progenitor proliferation.
      evidence:
      - reference: PMID:41758987
        reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice."
        explanation: Reports impaired colony formation in the edited HSPCs.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We used CRISPR/Cas9 to delete MDM4 in healthy donor hematopoietic stem and progenitor cells (HSPCs)."
    explanation: >
      Establishes the model system and that it is built on healthy-donor human
      primary cells.

- name: Patient-variant knock-in iPSC-derived hematopoiesis
  description: >
    Patient-specific MDM4 variants introduced into induced pluripotent stem
    cells, explicitly to test variant effects in a confounder-free genetic
    background. Complements the CRISPR HSPC model by testing the actual
    patient alleles rather than a deletion.
  experimental_model_type: IPSC_DERIVED_MODEL
  publication: PMID:41758987
  modeled_mechanisms:
  - target: Impaired HSPC Self-Renewal and Multilineage Output
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      Reduced erythroid and myeloid output with elevated p21, reproducing the
      multilineage deficit attributable to p53 hyperactivity.
    limitations: >-
      iPSC-derived haematopoiesis is developmentally distinct from adult
      bone-marrow haematopoiesis and is generally biased toward primitive or
      yolk-sac-like programmes, so a differentiation deficit measured here is
      not straightforwardly a statement about adult marrow. The system also
      cannot model the marrow niche or the decades-long clonal dynamics that
      the somatic TP53 arm of this disease turns on.
    readouts:
    - name: Erythroid and myeloid cell output
      target: Impaired HSPC Self-Renewal and Multilineage Output
      direction: DECREASED
      interpretation: Multilineage differentiation deficit in the patient genotypes.
      evidence:
      - reference: PMID:41758987
        reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
        explanation: Reports the reduced two-lineage output.
    - name: p21 expression
      target: Impaired HSPC Self-Renewal and Multilineage Output
      direction: INCREASED
      interpretation: p53 transcriptional-target readout confirming pathway activation.
      evidence:
      - reference: PMID:41758987
        reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "MDM4-mutant iPSCs yielded significantly reduced erythroid and myeloid cells and exhibited increased p53 activity, as evidenced by elevated p21 expression, confirming the role of MDM4 in regulating hematopoiesis through p53."
        explanation: p21 elevation is the reported p53-activity readout.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "To study variant effects in a confounder-free genetic background, we introduced patient-specific MDM4 variants into induced pluripotent stem cells (iPSCs)."
    explanation: >
      States the model and, usefully, the authors' reason for building it -
      isolating variant effect from patient background.

animal_models:
- name: Mdm4 p.T454M knock-in mouse
  species: Mouse
  genotype: Mdm4 p.T454M knock-in (the founding-family patient allele)
  publication: PMID:32300648
  description: >
    A knock-in of the actual patient allele, which is what makes it the
    best-matched model available for this disease. It resolves the limitation
    that caps the p53-delta-31 mouse below it: the lesion is in Mdm4, not in
    p53.
  modeled_mechanisms:
  - target: Telomere Shortening
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >
      Reproduces increased p53 activity, decreased telomere length and bone
      marrow failure in one animal carrying the human allele.
    limitations: >-
      Mouse telomeres are far longer than human telomeres and mice express
      telomerase more widely in somatic tissue, so the absolute shortening is
      not comparable and a mouse can tolerate attrition that would be
      pathological in a person. The model also covers only the missense
      p.T454M allele; the four truncating alleles from the 2026 cohort are
      unmodelled.
    readouts:
    - name: Telomere length
      target: Telomere Shortening
      direction: DECREASED
      interpretation: Direct measurement of the telomere phenotype in the patient genotype.
      evidence:
      - reference: PMID:32300648
        reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
        explanation: Reports decreased telomere length in the knock-in.
  - target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >
      The patient allele raises p53 activity in vivo, confirming in a whole
      organism what the human cell systems show.
    limitations: >-
      p53 target-gene programs and the tolerance of tissues to p53 activation
      differ between mouse and human, so the magnitude of activation does not
      transfer.
    readouts:
    - name: p53 activity
      target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
      direction: INCREASED
      interpretation: In vivo confirmation of the central mechanism.
      evidence:
      - reference: PMID:32300648
        reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
        explanation: Reports increased p53 activity in the knock-in.
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Variations in p53 activity markedly altered the phenotype of Mdm4 mutant mice, suggesting an explanation for the variable expressivity of disease symptoms in the family."
    explanation: >
      The model's most useful contribution beyond recapitulation: it supplies a
      mechanism for the variable expressivity seen in human carriers, by making
      p53 activity itself the modifier.

- name: p53 C-terminal truncation (p53 delta-31) mouse, Mdm4-dosage sensitized
  species: Mouse
  genotype: Trp53 delta-31 (C-terminal domain deletion), homozygous and heterozygous; Mdm4 dosage reduced
  publication: PMID:23770245
  description: >
    Not an MDM4 model in the first instance - it is a p53-activation model that
    was independently sensitized by lowering Mdm4. That makes it evidence
    about the axis rather than about the gene, which is why its fidelity is
    recorded as moderate and why its telomere findings are held in a
    HUMAN_MODEL_MISMATCH discussion rather than curated as human edges.
  modeled_mechanisms:
  - target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >
      Reproduces the causal direction - increased p53 activity produces
      aplastic anaemia, and reducing Mdm4 makes it dramatically worse - but
      arrives there by truncating p53 rather than by an MDM4 variant.
    limitations: >-
      The primary lesion is in p53 itself, not MDM4; Mdm4 dosage enters as a
      modifier. The mouse also develops pulmonary fibrosis and short telomeres,
      neither of which has been reported in human BMFS6, so the model's
      phenotype is broader than the human disease as currently described.
    readouts:
    - name: Aplastic anemia
      target: p53 Pathway Hyperactivation in Hematopoietic Stem and Progenitor Cells
      direction: INCREASED
      interpretation: >-
        Marrow failure arising directly from increased p53 activity, the
        mouse counterpart of the human haematopoietic phenotype.
      evidence:
      - reference: PMID:23770245
        reference_title: "Mutant mice lacking the p53 C-terminal domain model telomere syndromes."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "homozygous mutant mice expressing p53Δ31, a p53 lacking the C-terminal domain, exhibit increased p53 activity and suffer from aplastic anemia and pulmonary fibrosis, hallmarks of syndromes caused by short telomeres"
        explanation: Reports the marrow phenotype in the p53-hyperactive mouse.
  evidence:
  - reference: PMID:23770245
    reference_title: "Mutant mice lacking the p53 C-terminal domain model telomere syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms."
    explanation: >
      This is what makes the model informative for BMFS6 specifically: Mdm4
      dosage is the variable that converts a mild phenotype into a severe one.

genetic:
- name: MDM4
  gene_term:
    preferred_term: MDM4
    term:
      id: hgnc:6974
      label: MDM4
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >
    MDM4 (MDM4 regulator of p53) encodes a negative regulator of p53 that acts
    through a p53-binding domain and a RING-finger domain, both of which
    complementation studies show are required for its haematopoietic function.
    Germline heterozygous loss-of-function alleles - four null and two missense
    across the defining cohort - cause haploinsufficiency, and the pathway
    consequence of losing a p53 antagonist is p53 activation.
  review_notes: >-
    `relationship_type: CAUSATIVE` is well supported here despite the disease
    being newly defined, because the human genetics are backed by two
    orthogonal engineered systems (CRISPR-edited primary HSPCs and
    patient-variant knock-in iPSCs) plus domain-level complementation. There
    is no ClinGen gene-disease validity assertion for MDM4 in BMFS6 to cite.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mechanistically, MDM4 mutations are loss-of-function mutations leading to enhanced p53 activation."
    explanation: >
      States both the gene and the direction of effect that defines the
      mechanism.
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Complementation studies revealed both p53-binding and RING-finger domains as necessary for MDM4-mediated hematopoietic regulation."
    explanation: >
      Domain-level functional dissection supporting a specific, testable
      molecular role rather than a statistical association.

- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  relationship_type: COOPERATING
  variant_origin: SOMATIC
  features: >
    Somatically acquired loss-of-function TP53 mutations were found in one
    patient who progressed to MDS. TP53 is not a cause of BMFS6; it enters as
    the target of a somatic escape event on the germline background.
  notes: >
    Recorded as COOPERATING rather than CAUSATIVE or MODIFIER. The somatic
    event does not cause the disease and does not simply modify its severity -
    it relieves the germline mechanism while creating a new, worse risk, which
    is a cooperating alteration shaping disease behaviour.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, 1 patient with MDS acquired loss-of-function TP53 mutations, suggesting maladaptive somatic rescue."
    explanation: >
      Documents the somatic TP53 event and its proposed interpretation.

variants:
- name: MDM4 p.Thr454Met
  description: >-
    The founding allele, carried by the family in which BMFS6 was defined, and
    one of the two missense variants in the 2026 cohort - the one the cohort
    paper notes "had previously been associated with a familial BMF syndrome".
    It is the only MDM4 allele modelled as a knock-in mouse.
  gene:
    preferred_term: MDM4
    term:
      id: hgnc:6974
      label: MDM4
  type: SNV
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using a mouse model, we show that this mutation (p.T454M) leads to increased p53 activity, decreased telomere length, and bone marrow failure."
    explanation: >-
      Functional characterisation of this specific allele in vivo.

treatments:
- name: Hematopoietic Stem Cell Transplantation
  description: >
    Recorded from telomere-biology-disorder management guidance, not from
    BMFS6 data - no transplant outcome has been reported in an MDM4 carrier.
    The basis for importing it is that the founding family presented with
    features suggestive of dyskeratosis congenita and short telomeres, placing
    BMFS6 inside the class the source reviews. A reader should treat this as
    the expected standard of care for the class rather than as evidence about
    this gene.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:35929966
    reference_title: "The biology and management of dyskeratosis congenita and related disorders of telomeres."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: "Although hematological defects can respond to danazol/oxymetholone, the only current curative treatment for these is hematopoietic stem cell transplantation (HSCT) using fludarabine-based conditioning protocols."
    explanation: >
      Expert-view management statement for the telomere biology disorders.
      INDIRECT because the claim is about the disease class, and BMFS6's
      membership of that class rests on one family's phenotype.

- name: Androgen Therapy (Danazol or Oxymetholone)
  description: >
    Also class-level. Androgens are the non-transplant option for the
    haematological defect in telomere biology disorders. Untested in BMFS6, and
    mechanistically untested against a p53-driven proliferative block - the
    same caveat as above applies with less supporting analogy, since the
    androgen response in telomere disorders is generally attributed to
    telomerase upregulation rather than to relief of p53 pressure.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: danazol
      term:
        id: CHEBI:4315
        label: danazol
    - preferred_term: oxymetholone
      term:
        id: CHEBI:7864
        label: oxymetholone
  evidence:
  - reference: PMID:35929966
    reference_title: "The biology and management of dyskeratosis congenita and related disorders of telomeres."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: "Although hematological defects can respond to danazol/oxymetholone, the only current curative treatment for these is hematopoietic stem cell transplantation (HSCT) using fludarabine-based conditioning protocols."
    explanation: >
      Records the androgen option and, in the same sentence, its subordinate
      status to transplantation. INDIRECT for the same class-level reason.

- name: MDM2/MDMX inhibitors (nutlins and successors) - contraindicated on mechanistic grounds
  description: >
    Recorded as a treatment to avoid, not one to give, and recorded because it
    is the direct clinical consequence of this entry's organising claim.

    MDM2/MDMX inhibitors are developed for cancer precisely to raise p53
    activity - that is their intended pharmacology, not a side effect. BMFS6 is
    a disease of p53 hyperactivity caused by losing half the dose of MDMX
    (MDM4). Giving a drug whose mechanism is inhibition of that same axis would
    be expected to deepen the causal lesion rather than treat it, and the
    haematopoietic compartment is the one already demonstrably intolerant of
    the p53 pressure.

    The strength of this claim needs stating precisely. No publication makes
    this recommendation about BMFS6; no MDM2/MDMX inhibitor has been given to
    an MDM4-haploinsufficient patient, and no adverse outcome has been
    reported. The cited evidence establishes only the pharmacological premise -
    that these agents work by raising p53 activity. The contraindication
    follows from that premise plus this entry's own mechanism, in one inference
    step, which is why it is graded INDIRECT.

    It is nonetheless worth curating rather than leaving implicit. These agents
    are in clinical evaluation for haematological malignancy, BMFS6 patients
    present with hypocellular MDS and progress to leukaemia, and one reported
    patient acquired somatic TP53 loss - so an MDM4-haploinsufficient person
    reaching an oncology setting where an MDM2/MDMX inhibitor is on the menu is
    a foreseeable situation rather than a hypothetical one.
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:28673313
    reference_title: "MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer."
    supports: SUPPORT
    evidence_source: OTHER
    directness: INDIRECT
    snippet: "The pharmacological targeting of these two P53-regulators in order to restore or increase P53 expression and activity represents therefore a strategy for cancer therapy."
    explanation: >
      Establishes that MDM2/MDMX inhibition raises p53 activity by design.
      INDIRECT because the source is about cancer therapy and says nothing
      about BMFS6; the contraindication is an inference from this pharmacology
      plus this entry's mechanism, not a reported finding.

diagnosis:
- name: Bone Marrow Examination
  description: >
    Establishes marrow hypocellularity and identifies dysplastic change, which
    together define the presenting phenotype in this cohort.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 6 unrelated individuals with variable BMF phenotypes and hypocellular MDS, presenting at a median age of 10 years (range, 4 weeks to 53 years)."
    explanation: >
      The presenting phenotype is defined on marrow cellularity and dysplasia.

- name: Telomere Length Measurement
  description: >
    Worth performing, and worth interpreting cautiously. Short telomeres in the
    founding family are what first suggested a telomere biology disorder, so a
    short result supports the diagnosis - but the 2026 cohort was not measured,
    so a normal result does not currently exclude BMFS6.
  evidence:
  - reference: PMID:32300648
    reference_title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a germline missense mutation of MDM4, a negative regulator of p53, was found in a family with features suggestive of dyskeratosis congenita, e.g., bone marrow hypocellularity, short telomeres, tongue squamous cell carcinoma, and acute myeloid leukemia"
    explanation: >
      Short telomeres were part of the presentation that defined the disease.

- name: Germline Molecular Genetic Testing of MDM4
  description: >
    Confirmatory. Note that four of the six reported alleles are truncating
    and were confirmed at transcript level by RNA sequencing, so RNA-level
    confirmation is worth having for splice-region candidates rather than
    relying on DNA-level prediction alone.
  evidence:
  - reference: PMID:41758987
    reference_title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF syndrome."
    explanation: >
      Documents the diagnostic finding and the RNA-level confirmation step.

references:
- reference: PMID:41758987
  title: "MDM4 haploinsufficiency leads to p53-mediated bone marrow failure."
- reference: PMID:23770245
  title: "Mutant mice lacking the p53 C-terminal domain model telomere syndromes."
- reference: PMID:32300648
  title: "Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance."
- reference: PMID:35929966
  title: "The biology and management of dyskeratosis congenita and related disorders of telomeres."
- reference: PMID:28673313
  title: "MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer."
📚

References & Deep Research

References

5
PMID:41758987
MDM4 haploinsufficiency leads to p53-mediated bone marrow failure.
No top-level findings curated for this source.
PMID:23770245
Mutant mice lacking the p53 C-terminal domain model telomere syndromes.
No top-level findings curated for this source.
PMID:32300648
Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance.
No top-level findings curated for this source.
PMID:35929966
The biology and management of dyskeratosis congenita and related disorders of telomeres.
No top-level findings curated for this source.
PMID:28673313
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
No top-level findings curated for this source.

Deep Research

1
OpenScientist ▸
Key Findings
openscientist-autonomous 5 citations 2026-08-30T18:47:05.162779

Key Findings

Finding 1 — BMFS6 is caused by germline heterozygous loss-of-function MDM4 variants

The molecular etiology of BMFS6 was established by Sharma et al. (2026) in a cohort of 6 unrelated individuals with variable bone marrow failure and hypocellular myelodysplastic syndrome (MDS). Genomic analysis identified germline heterozygous variants in MDM4: four null variants (frameshift, nonsense, and splice-site alleles resulting in premature truncation, confirmed at the transcript level by RNA sequencing) and two missense variants, one of which had previously been associated with a familial BMF syndrome. The authors explicitly classified the disease-causing variants as loss-of-function.

"Genomic analysis revealed germ line heterozygous variants in mouse double minute 4 (MDM4), including 4 null (frameshift, nonsense, and splice site resulting in premature truncation confirmed by RNA sequencing) and 2 missense variants, of which 1 had previously been associated with a familial BMF syndrome." — PMID: 41758987

"Mechanistically, MDM4 mutations are loss-of-function mutations leading to enhanced p53 activation." — PMID: 41758987

This establishes both the causal gene (MDM4) and the direction of effect (haploinsufficiency/LOF, not gain-of-function). The onset was strikingly variable, with a median age of ~10 years spanning a range from 4 weeks to 53 years — a hallmark of variable expressivity typical of p53-pathway IBMFS.

Finding 2 — Mechanism: MDM4 haploinsufficiency impairs HSPCs via p53 activation

The causal chain from genotype to phenotype was demonstrated with orthogonal functional models:

  • CRISPR/Cas9 editing of healthy-donor HSPCs to produce MDM4-haploinsufficient cells caused increased p53 activity, impaired colony-forming capacity, and reduced engraftment in immunodeficient mice.
  • Patient-specific MDM4 variants introduced into iPSCs produced significantly reduced erythroid and myeloid output with increased p53 activity (elevated p21).
  • Complementation studies showed that both the p53-binding domain and the RING-finger domain of MDM4 are necessary for its hematopoietic regulatory function.

"The resulting MDM4-haploinsufficient HSPCs exhibited increased p53 activity, impaired colony-forming capacity, and reduced engraftment potential in immunodeficient mice." — PMID: 41758987

"Complementation studies revealed both p53-binding and RING-finger domains as necessary for MDM4-mediated hematopoietic regulation." — PMID: 41758987

This is direct, cell-autonomous evidence that reduced MDM4 dosage → p53/p21 hyperactivation → impaired HSPC self-renewal and differentiation → marrow failure.

Finding 3 — Mouse models link Mdm4 dosage and p53 activity to BMF/telomere phenotypes

Independent mouse genetics anticipated and corroborate the human mechanism. Simeonova et al. (2013) showed that homozygous p53^Δ31/Δ31^ mice (which carry a p53 lacking the C-terminal domain and therefore have increased p53 activity) develop aplastic anemia and pulmonary fibrosis with short telomeres — hallmarks of dyskeratosis congenita / Hoyeraal-Hreidarsson syndrome — accompanied by downregulation of several telomere-maintenance genes (Dkc1/Dyskerin, Rtel1, Tinf2, Terf1). Critically, heterozygous p53^+/Δ31^ mice were only mildly affected, but reducing Mdm4 levels dramatically aggravated their symptoms.

"Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms." — PMID: 23770245

"homozygous mutant mice expressing p53Δ31, a p53 lacking the C-terminal domain, exhibit increased p53 activity and suffer from aplastic anemia and pulmonary fibrosis, hallmarks of syndromes caused by short telomeres" — PMID: 23770245

This provides a causal genetic link between Mdm4 gene dosage, p53 activation, and bone marrow failure with telomere shortening — the exact triad seen in human BMFS6.

Finding 4 — ClinVar classification lags the literature

A ClinVar query (August 2026) for MDM4 returned 18 pathogenic/likely-pathogenic records, but nearly all are large 1q21–q44 copy-number gains/losses (contiguous-gene chromosomal events), not the single-nucleotide/indel BMFS6 alleles. The founding familial variant NM_002393.5(MDM4):c.1361C>T (p.Thr454Met) is currently classified as Uncertain significance (VUS), and the truncating LOF alleles from the 2026 cohort are not yet broadly deposited or classified. This reflects the recency of BMFS6's molecular definition and creates a practical diagnostic gap: current variant-classification databases will not yet flag causal BMFS6 alleles as pathogenic despite strong functional evidence.

Finding 5 — DC-like multisystem phenotype; founding variant maps to the RING domain

The OMIM #618849 clinical synopsis (via Monarch, MONDO:0030015) annotates BMFS6 with a broad, dyskeratosis-congenita-like phenotype spectrum. UniProt O15151 (490 aa) domain mapping places the founding p.Thr454Met variant within the C-terminal RING-type zinc finger (aa 437–478); other functional domains are the SWIB/MDM2 p53-binding domain (aa 25–108) and a RanBP2-type zinc finger (aa 300–329).

"Dyskeratosis congenita is a cancer-prone inherited bone marrow failure syndrome caused by telomere dysfunction." — PMID: 32300648

Finding 6 — Curated GO annotations confirm MDM4 as a p53-signaling suppressor

QuickGO curated annotations for MDM4 (UniProt O15151) independently corroborate its role as a negative regulator of p53, including negative regulation of signal transduction by p53 class mediator (GO:1901797), DNA damage response, signal transduction by p53 class mediator (GO:0030330), negative regulation of intrinsic apoptotic signaling by p53 class mediator (GO:1902254), negative regulation of apoptotic process (GO:0043066), zinc ion binding (GO:0008270), and nuclear localization (GO:0005634/GO:0005654). MDM4 is also annotated to cardiac developmental processes (GO:0003170/0003181/0003203/0003281/0003283), consistent with its essential embryonic role. These curated annotations biologically ground the LOF model: losing an established p53 suppressor produces p53 hyperactivity.

Section-by-Section Disease Characterization

1. Disease Information

BMFS6 is an ultra-rare autosomal dominant inherited bone marrow failure and MDS/leukemia-predisposition syndrome characterized by variable cytopenias, hypocellular marrow, and dyskeratosis-congenita–like multisystem features. It results from germline haploinsufficiency of MDM4.

Identifier type Value
OMIM #618849
MONDO MONDO:0030015
Gene MDM4 (MDMX), 1q32.1; HGNC:6974; UniProt O15151
ICD-10 / ICD-11 No specific code; maps approximately to D61.9 (aplastic anemia, unspecified) / 3A70
MeSH Closest: Bone Marrow Failure Disorders; Anemia, Aplastic

Synonyms / alternative names: BMFS6; MDM4-related bone marrow failure syndrome; MDM4-related dyskeratosis congenita spectrum disorder; MDM4 haploinsufficiency syndrome.

Information source type: Primarily aggregated disease-level resources (OMIM, Monarch/MONDO, UniProt, ClinVar, QuickGO) plus individual-patient case-cohort data (the 6-patient 2026 cohort and the founding family).

2. Etiology

  • Primary cause: Genetic — germline heterozygous LOF variants in MDM4 (Finding 1). No environmental or infectious cause is required.
  • Genetic risk factors: The causal variants themselves (null and missense LOF alleles). The p53 pathway is dosage-sensitive; any allele reducing MDM4 restraint of p53 predisposes to marrow failure.
  • Modifier factors: Telomere-maintenance gene status and background p53-pathway tone likely modulate severity, as suggested by mouse genetics (Finding 3), but specific human modifiers are not yet defined.
  • Environmental / protective factors / gene-environment interactions: Not established for BMFS6. Given the p53-driven mechanism, exposures that induce DNA damage or genotoxic stress (chemotherapy, radiation) would be expected to further activate p53 and could worsen marrow failure — a theoretical consideration relevant to conditioning regimens.

3. Phenotypes

From OMIM #618849 clinical synopsis (Finding 5), with suggested HPO terms and typical characteristics:

Phenotype HPO term Type Notes
Bone marrow hypocellularity HP:0005528 Laboratory/pathology Core feature; hypocellular MDS
Anemia HP:0001903 Laboratory Variable severity
Neutropenia HP:0001875 Laboratory Variable
Lymphopenia HP:0001888 Laboratory Variable
Macrocytosis / increased MCV HP:0005518 Laboratory Stress-erythropoiesis marker
Persistence of fetal hemoglobin HP:0011904 Laboratory DC-spectrum marker
Short telomere length HP:0031413 Laboratory Links to telomere biology
Squamous cell carcinoma of the tongue HP:0030413 Clinical/neoplasm Cancer predisposition
Recurrent sinusitis HP:0011108 Clinical Immune involvement
Hypothyroidism HP:0000821 Clinical Endocrine involvement
Osteopenia HP:0000938 Clinical Skeletal
Chronic fatigue HP:0012432 Symptom Constitutional
Myalgia HP:0003326 Symptom Constitutional

Onset: highly variable (4 weeks–53 years; median ~10 years). Severity/progression: variable, ranging from mild cytopenias to hypocellular MDS; progressive marrow failure and cancer risk over time. Frequency: because the cohort is only 6 individuals, per-phenotype frequencies are qualitative rather than precisely quantified. Quality of life: dominated by cytopenia complications (fatigue, infection, transfusion dependence) and cancer surveillance burden; no disease-specific QoL instrument exists.

4. Genetic / Molecular Information

  • Causal gene: MDM4 (MDMX), 1q32.1; HGNC:6974; UniProt O15151 (490 aa).
  • Variant spectrum (Finding 1): 4 null (frameshift, nonsense, splice-site → premature truncation, RNA-seq confirmed) + 2 missense. Founding allele: NM_002393.5:c.1361C>T (p.Thr454Met), in the RING domain (aa 437–478).
  • ACMG classification (Finding 4): p.Thr454Met currently VUS in ClinVar; truncating alleles not yet broadly classified despite functional LOF evidence. Most ClinVar MDM4 pathogenic entries are large 1q CNVs, not BMFS6 point variants.
  • Allele frequency: Causal alleles are private/ultra-rare; expected absent or vanishingly rare in gnomAD (consistent with a dominant, deleterious constraint on this p53 regulator).
  • Origin: Germline (heterozygous). Somatic MDM4 amplification is an oncogenic event in cancers but is mechanistically opposite to BMFS6 LOF.
  • Functional consequence: Loss of function / haploinsufficiency → enhanced p53 activation (Findings 1, 2, 6).
  • Domain architecture (UniProt O15151): SWIB/MDM2 p53-binding domain (aa 25–108); RanBP2-type zinc finger (aa 300–329); RING-type zinc finger (aa 437–478, contains the founding variant). Complementation shows both the p53-binding and RING domains are required for hematopoietic function (Finding 2).
  • Epigenetic / chromosomal: No BMFS6-specific epigenetic signature reported. Large 1q32 CNVs encompassing MDM4 exist in ClinVar but represent contiguous-gene syndromes rather than isolated BMFS6.

5. Environmental Information

BMFS6 is a monogenic germline disorder; no environmental, lifestyle, or infectious cause is required or established. Genotoxic exposures (radiation, chemotherapy) are a theoretical aggravating consideration because they further activate p53 in an already p53-sensitized system.

6. Mechanism / Pathophysiology

Causal chain:

Germline heterozygous LOF variant in MDM4 (null or missense)
│  (haploinsufficiency — ~50% functional MDM4)
▼
Reduced MDM4 restraint of p53  (p53-binding + RING domains both required)
│
▼
Chronic p53 hyperactivation  →  ↑ p21 (CDKN1A)
│
▼
Impaired HSPC proliferation, differentiation & self-renewal
   (↓ colony formation, ↓ erythroid/myeloid output, ↓ engraftment)
│
▼
Bone marrow hypocellularity / cytopenias / hypocellular MDS
   + DC-spectrum features (short telomeres, ↑HbF, macrocytosis)
│
▼
Progressive marrow failure ± cancer (tongue SCC), multisystem involvement
  • Molecular pathway: p53 signaling (upstream MDM4/MDM2 → downstream p53 → p21/apoptotic targets). MDM4 also has p53-independent roles (RB regulation, genome stability) reported in the broader literature, but the BMFS6 mechanism is p53-dependent.
  • Cellular processes (GO): negative regulation of p53-class signal transduction (GO:1901797); intrinsic apoptotic signaling by p53 mediator (GO:1902254); cell cycle regulation (GO:0051726); negative regulation of cell proliferation (GO:0008285). Loss of MDM4 shifts the balance toward cell-cycle arrest and apoptosis in HSPCs.
  • Cell types (CL): hematopoietic stem cell (CL:0000037); common myeloid progenitor (CL:0000049); erythroid progenitor (CL:0000038); the primary target is the bone marrow HSPC compartment.
  • Upstream vs downstream: MDM4 haploinsufficiency is the upstream trigger; p53/p21 hyperactivation is the proximal effector; HSPC attrition and cytopenias are downstream clinical outputs.
  • Subcellular (GO CC): nucleus (GO:0005634), nucleoplasm (GO:0005654) — where MDM4 regulates p53.
  • Molecular profiling: RNA-seq confirmed premature truncation of null alleles (Finding 1); iPSC/HSPC models show elevated p21 (Finding 2). No large-scale patient transcriptome/proteome/metabolome datasets are yet published.

7. Anatomical Structures Affected

  • Primary organ: Bone marrow (UBERON:0002371) / hematopoietic system (UBERON:0002390).
  • Cells targeted: HSPCs (CL:0000037) and downstream erythroid/myeloid progenitors.
  • Secondary/multisystem involvement: tongue (UBERON:0001723; squamous cell carcinoma), thyroid (UBERON:0002046; hypothyroidism), skeleton (UBERON:0004288; osteopenia), paranasal sinuses (UBERON:0002100; recurrent sinusitis), and lung (fibrosis in the mouse model).
  • Subcellular compartment: nucleus (GO:0005634).
  • Lateralization: systemic/bilateral (marrow is a distributed organ); no lateralization applies.

8. Temporal Development

  • Onset: Congenital to adult; 4 weeks to 53 years (median ~10 years) — remarkably variable (Finding 1).
  • Pattern: Chronic, insidious, progressive marrow failure; can present acutely with severe cytopenia or be discovered incidentally.
  • Stages: cytopenia → marrow hypocellularity/hypocellular MDS → potential clonal evolution/leukemia; lifelong disease.
  • Critical periods: Genotoxic stress and HSCT conditioning are potential windows of vulnerability given p53 sensitization.

9. Inheritance and Population

  • Inheritance: Autosomal dominant (germline heterozygous LOF); consistent with a dosage-sensitive p53 regulator.
  • Penetrance/expressivity: Variable expressivity is prominent (wide onset range, multisystem spectrum); penetrance not precisely quantified due to small numbers.
  • Epidemiology: Ultra-rare. No prevalence/incidence estimates exist; defined by 6 unrelated individuals plus a founding family. No established founder effect, sex bias, or ethnic predilection.
  • Carrier frequency: Not applicable in the classical recessive sense; dominant transmission with likely de novo and inherited alleles.

10. Diagnostics

  • Laboratory: CBC (anemia HP:0001903, neutropenia HP:0001875, lymphopenia HP:0001888), MCV (macrocytosis HP:0005518), HbF quantification (HP:0011904), telomere length testing (flow-FISH; short telomeres HP:0031413), bone marrow aspirate/biopsy (hypocellularity HP:0005528, MDS assessment).
  • Genetic testing (recommended approach): Because BMFS6 is one of many IBMFS, an inherited-bone-marrow-failure/telomere gene panel or exome/genome sequencing including MDM4 is the diagnostic route. Single-gene MDM4 testing applies when the syndrome is suspected. RNA sequencing helped confirm splice/truncating consequences (Finding 1). Note the ClinVar classification gap (Finding 4): causal alleles may return as VUS, so functional/segregation interpretation is important.
  • Differential diagnosis: dyskeratosis congenita and other telomere biology disorders, Fanconi anemia, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency, other IBMFS/MDS-predisposition syndromes. Short telomeres + p53-pathway variant + multisystem DC-like features distinguish BMFS6.
  • Screening: Cascade genetic testing of at-risk relatives; marrow and cancer (e.g., oral/tongue) surveillance in carriers.

11. Outcome / Prognosis

  • Course: Chronic, progressive marrow failure with risk of hypocellular MDS and clonal evolution; cancer predisposition (tongue SCC).
  • Prognostic factors: severity/onset of cytopenias, marrow cellularity, telomere length, and clonal/MDS status.
  • Survival: Not quantified (ultra-rare, recent definition). By analogy to DC-spectrum IBMFS, outcomes depend on marrow failure severity, HSCT success, and cancer.
  • Complications: transfusion dependence, infection, bleeding, MDS/leukemic transformation, solid tumors, pulmonary fibrosis (as in the mouse model), endocrine and skeletal morbidity.

12. Treatment

  • Supportive care: transfusions, growth factors, infection prophylaxis — standard IBMFS management.
  • Definitive therapy: Allogeneic hematopoietic stem cell transplantation (HSCT) (NCIT:C15431) for marrow failure/MDS; reduced-intensity conditioning is generally favored in DC-spectrum disorders given genotoxic sensitivity.
  • Mechanistically contraindicated: p53-activating MDM2/MDMX inhibitors (nutlins and related agents) would further raise p53 activity in an already p53-hyperactive system and are therefore contraindicated in BMFS6 — a key actionable insight derived directly from the LOF mechanism (Findings 1, 2, 6). (Conversely, these agents are being developed as anticancer therapies precisely because they raise p53; PMID: 28673313, PMID: 21075910.)
  • Theoretical/experimental: targeted p53 pathway modulation to dampen excess p53 signaling is conceptually attractive but unproven and must balance cancer-predisposition risk. No BMFS6-specific clinical trials exist.
  • Genotype-guided care: genetic diagnosis directs HSCT donor selection (avoid affected relatives), conditioning intensity, and cancer surveillance.

13. Prevention

  • Primary: Not preventable (germline). Genetic counseling for the autosomal-dominant trait; reproductive options include prenatal testing and preimplantation genetic diagnosis for known familial variants.
  • Secondary: Cascade testing of relatives; surveillance CBCs, marrow evaluation, and oral/tongue cancer screening in carriers.
  • Tertiary: Prevent complications via infection prophylaxis, transfusion support, avoidance of unnecessary genotoxic exposures, and timely HSCT.
  • Counseling: Autosomal-dominant recurrence risk (~50% to offspring of an affected carrier); VUS status of causal alleles (Finding 4) must be communicated carefully.

14. Other Species / Natural Disease

  • Orthologs: Mouse Mdm4 (NCBI Gene 17248); the gene name derives from "mouse double minute 4." Human MDM4: NCBI Gene 4194.
  • Natural disease in other species: No naturally occurring companion-animal BMFS6 equivalent is documented. The disease knowledge is human plus engineered/induced mouse models.
  • Evolutionary conservation: The MDM4–p53 regulatory axis is deeply conserved across vertebrates, and cardiac/embryonic developmental annotations (Finding 6) reflect this essential conserved role.

15. Model Organisms

  • Mouse (in vivo): p53^Δ31^ mice with reduced Mdm4 dosage recapitulate aplastic anemia, short telomeres, and pulmonary fibrosis (Finding 3; PMID: 23770245). Xenograft/engraftment assays in immunodeficient mice show reduced engraftment of MDM4-haploinsufficient human HSPCs (Finding 2).
  • Cellular/human (in vitro): CRISPR/Cas9-edited healthy-donor HSPCs and patient-variant iPSCs with erythroid/myeloid differentiation readouts recapitulate impaired blood output with p53/p21 elevation (Finding 2).
  • Phenotype recapitulation: Strong for the hematopoietic and telomere/marrow-failure axis. Limitations: Full multisystem human spectrum (e.g., tongue SCC, hypothyroidism) is not comprehensively modeled; complete Mdm4 knockout is embryonic lethal (p53-dependent), so dosage/conditional models are required.

Mechanistic Model / Interpretation

BMFS6 is best understood as a "too much p53" bone marrow failure syndrome, mechanistically the mirror image of cancers that amplify MDM4 to silence p53. In healthy hematopoiesis, MDM4 (together with MDM2) restrains p53 so that HSPCs can proliferate and differentiate. A germline LOF hit that removes ~half of functional MDM4 tips this balance toward chronic p53/p21 activation, which enforces cell-cycle arrest and apoptosis in the very stem/progenitor compartment that must expand to sustain blood production. The result is a hypocellular marrow and cytopenias, with overlapping telomere-maintenance dysregulation that produces the dyskeratosis-congenita-like phenotype.

Layer BMFS6 (this disease) Opposite state (cancer)
MDM4 dosage ↓ (haploinsufficiency) ↑ (amplification/overexpression)
p53 activity ↑ (hyperactive) ↓ (suppressed)
HSPC fate arrest/apoptosis → marrow failure survival/proliferation → tumor growth
Therapeutic logic avoid p53 activators (nutlins) use p53 activators (nutlins)

Three independent evidence streams converge on this model: (1) human genetics + functional HSPC/iPSC assays (Findings 1, 2); (2) mouse Mdm4-dosage genetics (Finding 3); and (3) curated GO/UniProt annotations of MDM4 as a p53 suppressor (Findings 5, 6). The convergence across human, animal, and in-vitro evidence, plus the mechanistically explicit therapeutic contraindication, makes this one of the more cleanly delineated inherited BMF mechanisms.

Evidence Base

PMID Title (abbrev.) Role in this report
41758987 MDM4 haploinsufficiency leads to p53-mediated bone marrow failure Defining paper. Establishes MDM4 LOF etiology in 6 individuals; functional HSPC/iPSC proof; domain mapping (Findings 1, 2)
32300648 Germline mutation of MDM4 (founding family) Founding p.Thr454Met family; frames the DC-like, cancer-prone, telomere-associated nature (Finding 5)
23770245 Mutant mice lacking the p53 C-terminal domain model telomere syndromes Mouse genetics: reduced Mdm4 aggravates p53-driven aplastic anemia/telomere syndrome (Finding 3)
37834388 p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes Review situating p53 hyperactivity as a shared BMFS mechanism
28673313 MDM2/X inhibitors under clinical evaluation Establishes that MDM2/MDMX inhibitors raise p53 — basis for the contraindication in BMFS6
21075910 A small-molecule inhibitor of MDMX activates p53 and induces apoptosis Confirms MDMX inhibition activates p53/apoptosis — reinforces contraindication
24755078 / 32075226 MdmX RING domain studies Structural/functional context for why the RING domain is essential (Finding 2)
25703327 / 24608433 MDMX p53-independent roles (RB, genome stability) Context for additional MDM4 functions not central to BMFS6

Evidence-source classification: Findings 1, 2 combine human clinical (cohort genetics) with in-vitro (HSPC/iPSC) and model-organism (mouse engraftment) evidence; Finding 3 is model organism; Findings 4, 5, 6 are database/curation-derived (ClinVar, OMIM/Monarch, UniProt, QuickGO).

Limitations and Knowledge Gaps

  1. Small cohort. The disease is defined by 6 unrelated individuals plus a founding family; per-phenotype frequencies, penetrance, and natural history are qualitative, not quantitative.
  2. Variant-classification lag (Finding 4). The founding p.Thr454Met is a VUS in ClinVar and truncating alleles are not yet broadly deposited, creating a real-world diagnostic interpretation gap despite strong functional evidence.
  3. No epidemiology. Prevalence, incidence, sex ratio, and geographic/ethnic distribution are unknown.
  4. No omics-scale patient datasets. No published patient transcriptome/proteome/metabolome/single-cell studies; molecular profiling is limited to targeted RNA-seq and p21 readouts.
  5. Incomplete multisystem modeling. Mouse and cellular models capture the hematopoietic/telomere axis well but not the full extra-hematopoietic spectrum (tongue SCC, hypothyroidism, osteopenia).
  6. Therapeutics unproven. HSCT is inferred from general IBMFS practice; no BMFS6-specific trials exist, and p53-dampening strategies remain conceptual and risk-laden.
  7. Modifiers undefined. Human genetic/environmental modifiers of the highly variable onset (4 weeks–53 years) are not identified.

Proposed Follow-up Experiments / Actions

  1. Deposit and classify variants. Submit the 2026 cohort's null and missense MDM4 alleles to ClinVar with functional evidence to move them beyond VUS (addresses Finding 4).
  2. Expand the cohort / registry. Establish an international BMFS6 registry via GeneMatcher/Matchmaker Exchange to quantify penetrance, expressivity, natural history, and cancer risk.
  3. Telomere biology. Systematically measure telomere length and telomere-gene expression in patients to test the DC-spectrum link suggested by mouse data (Finding 3).
  4. Single-cell HSPC profiling. scRNA-seq of patient marrow/iPSC-HSPCs to map p53-target activation and identify the specific arrested/apoptotic progenitor populations (CL terms).
  5. Therapeutic modeling. Test whether transient, controlled dampening of p53 signaling rescues HSPC output in patient iPSC models — carefully weighing cancer-predisposition risk — and formally document the nutlin/MDM2-MDMX-inhibitor contraindication.
  6. HSCT outcomes study. Collate transplant outcomes and optimal conditioning intensity for BMFS6, given the telomere/p53 genotoxic-sensitivity concern.
  7. Genotype–phenotype correlation. Compare RING-domain (e.g., p.Thr454Met) vs null vs p53-binding-domain variants for severity, leveraging the complementation finding that both domains are functionally required (Finding 2).

Consensus Answer

Bone Marrow Failure Syndrome 6 (BMFS6; OMIM #618849, MONDO:0030015) is an ultra-rare autosomal dominant inherited bone marrow failure and MDS-predisposition syndrome caused by germline heterozygous loss-of-function variants in MDM4 (MDMX; 1q32.1), a principal negative regulator of p53. MDM4 haploinsufficiency releases p53 restraint, causing p53/p21 hyperactivation that impairs hematopoietic stem/progenitor cell proliferation, differentiation, and engraftment — producing variable cytopenias, marrow hypocellularity, and dyskeratosis-congenita-like multisystem features with onset from 4 weeks to 53 years. Management follows inherited BMF principles (surveillance, supportive care, allogeneic HSCT) with genetic counseling, and p53-activating MDM2/MDMX inhibitors are mechanistically contraindicated.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 10
Resolved 10
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 7
Quoted claims found in source 7
Quoted claims not found in source 0
References weighed for topical relevance 10
On topic 4
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 35
Resolved 34
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 23
Terms named correctly 13
Terms named as a different term 2
Terms whose name is worth a second look 8

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0030015 (4 mentions) - the report calls it "MONDO"; MONDO calls it bone marrow failure syndrome 6
  • CL:0000037 (2 mentions) - the report calls it "Cells targeted: HSPCs"; CL calls it hematopoietic stem cell**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • GO:1902254 (2 mentions) - the report calls it "negative regulation of intrinsic apoptotic signaling by p53 class mediator"; GO calls it negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator
  • GO:0005634 (3 mentions) - the report calls it "Subcellular compartment: nucleus"; GO calls it nucleus**, and lists "cell nucleus" among its other names
  • HP:0001875 (2 mentions) - the report calls it "Neutropenia"; HP calls it Decreased total neutrophil count, and lists "Neutropenia" among its other names
  • HP:0001888 (2 mentions) - the report calls it "Lymphopenia"; HP calls it Decreased total lymphocyte count, and lists "Lymphopenia" among its other names
  • HP:0005518 (2 mentions) - the report calls it "Macrocytosis / increased MCV"; HP calls it Increased mean corpuscular volume, and lists "Increased MCV" among its other names
  • HP:0011904 (2 mentions) - the report calls it "Persistence of fetal hemoglobin"; HP calls it Persistence of hemoglobin F
  • UBERON:0002371 (1 mention) - the report calls it "Primary organ: Bone marrow"; UBERON calls it bone marrow**
  • NCIT:C15431 (1 mention) - the report calls it "Allogeneic hematopoietic stem cell transplantation (HSCT)"; NCIT calls it Hematopoietic Cell Transplantation, and lists "Hematopoietic Stem Cell Transplantation" among its other names